VelaVigo
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $60M
Overview
A biotech developing novel therapeutics for neurodegenerative diseases through targeted neuronal pathway modulation.
Neuroscience
Technology Platform
A proprietary platform focused on modulating specific neuronal survival and synaptic function pathways implicated in neurodegeneration.
Funding History
1Total raised:$60M
PIPE$60M
Opportunities
Potential to address massive unmet needs in aging populations with a first-in-class disease-modifying therapy.
Risk Factors
High biological risk of novel neuroscience targets and the historical difficulty of developing successful CNS drugs.
Competitive Landscape
Operates in the intensely competitive and high-failure-risk neurodegenerative space, competing with large pharma and well-funded biotechs like Biogen and Denali.